Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Айдек Ма Инк., Дзе Риджентс Оф Дзе Юниверсити Оф КалифорнияfiledCriticalБайоджен Айдек Ма Инк.
Publication of UA90242C2publicationCriticalpatent/UA90242C2/en
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Abstract
A monoclonal antibody that specifically binds to αβand inhibits the binding of αβto latency associated peptide (LAP) with an ICvalue lower than that of 10D5. The invention further relates to a hybridoma producing the antibody (ATCC accession number PTA-3647, PTA-3649, PTA-3645, PTA-3646, PTA-3898, PTA-3899, PTA-3900), to a method of detecting αβa tissue sample from a mammal, a composition for preventing or treating a disease mediated by αβin a mammal, and use of the composition for the preparation of medicinal agent.
UA20041008265A2002-03-132003-03-13MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TO αVβ6
UA90242C2
(en)
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
Antibody that preferentially binds cell-associated ca 125/0722p relative to shed ca125/0722p, pharmaceutical composition comprising same and use thereof for preparation of medicament